A Mosaic Nanoparticle Vaccine Elicits Potent Mucosal Immune Response with Significant Cross‐Protection Activity against Multiple SARS‐CoV‐2 Sublineages
Because of the rapid mutation and high airborne transmission of SARS‐CoV‐2, a universal vaccine preventing the infection in the upper respiratory tract is particularly urgent. Here, a mosaic receptor‐binding domain (RBD) nanoparticle (NP) vaccine is developed, which induces more RBD‐targeted type IV...
Saved in:
| Published in | Advanced science Vol. 10; no. 27; pp. e2301034 - n/a |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Germany
John Wiley & Sons, Inc
01.09.2023
John Wiley and Sons Inc Wiley |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2198-3844 2198-3844 |
| DOI | 10.1002/advs.202301034 |
Cover
| Abstract | Because of the rapid mutation and high airborne transmission of SARS‐CoV‐2, a universal vaccine preventing the infection in the upper respiratory tract is particularly urgent. Here, a mosaic receptor‐binding domain (RBD) nanoparticle (NP) vaccine is developed, which induces more RBD‐targeted type IV neutralizing antibodies (NAbs) and exhibits broad cross‐protective activity against multiple SARS‐CoV‐2 sublineages including the newly‐emerged BF.7, BQ.1, XBB. As several T‐cell‐reactive epitopes, which are highly conserved in sarbecoviruses, are displayed on the NP surface, it also provokes potent and cross‐reactive cellular immune responses in the respiratory tissue. Through intranasal delivery, it elicits robust mucosal immune responses and full protection without any adjuvants. Therefore, this intranasal mosaic NP vaccine can be further developed as a pan‐sarbecovirus vaccine to block the viral entrance from the upper respiratory tract. |
|---|---|
| AbstractList | Because of the rapid mutation and high airborne transmission of SARS-CoV-2, a universal vaccine preventing the infection in the upper respiratory tract is particularly urgent. Here, a mosaic receptor-binding domain (RBD) nanoparticle (NP) vaccine is developed, which induces more RBD-targeted type IV neutralizing antibodies (NAbs) and exhibits broad cross-protective activity against multiple SARS-CoV-2 sublineages including the newly-emerged BF.7, BQ.1, XBB. As several T-cell-reactive epitopes, which are highly conserved in sarbecoviruses, are displayed on the NP surface, it also provokes potent and cross-reactive cellular immune responses in the respiratory tissue. Through intranasal delivery, it elicits robust mucosal immune responses and full protection without any adjuvants. Therefore, this intranasal mosaic NP vaccine can be further developed as a pan-sarbecovirus vaccine to block the viral entrance from the upper respiratory tract.Because of the rapid mutation and high airborne transmission of SARS-CoV-2, a universal vaccine preventing the infection in the upper respiratory tract is particularly urgent. Here, a mosaic receptor-binding domain (RBD) nanoparticle (NP) vaccine is developed, which induces more RBD-targeted type IV neutralizing antibodies (NAbs) and exhibits broad cross-protective activity against multiple SARS-CoV-2 sublineages including the newly-emerged BF.7, BQ.1, XBB. As several T-cell-reactive epitopes, which are highly conserved in sarbecoviruses, are displayed on the NP surface, it also provokes potent and cross-reactive cellular immune responses in the respiratory tissue. Through intranasal delivery, it elicits robust mucosal immune responses and full protection without any adjuvants. Therefore, this intranasal mosaic NP vaccine can be further developed as a pan-sarbecovirus vaccine to block the viral entrance from the upper respiratory tract. Abstract Because of the rapid mutation and high airborne transmission of SARS‐CoV‐2, a universal vaccine preventing the infection in the upper respiratory tract is particularly urgent. Here, a mosaic receptor‐binding domain (RBD) nanoparticle (NP) vaccine is developed, which induces more RBD‐targeted type IV neutralizing antibodies (NAbs) and exhibits broad cross‐protective activity against multiple SARS‐CoV‐2 sublineages including the newly‐emerged BF.7, BQ.1, XBB. As several T‐cell‐reactive epitopes, which are highly conserved in sarbecoviruses, are displayed on the NP surface, it also provokes potent and cross‐reactive cellular immune responses in the respiratory tissue. Through intranasal delivery, it elicits robust mucosal immune responses and full protection without any adjuvants. Therefore, this intranasal mosaic NP vaccine can be further developed as a pan‐sarbecovirus vaccine to block the viral entrance from the upper respiratory tract. Because of the rapid mutation and high airborne transmission of SARS‐CoV‐2, a universal vaccine preventing the infection in the upper respiratory tract is particularly urgent. Here, a mosaic receptor‐binding domain (RBD) nanoparticle (NP) vaccine is developed, which induces more RBD‐targeted type IV neutralizing antibodies (NAbs) and exhibits broad cross‐protective activity against multiple SARS‐CoV‐2 sublineages including the newly‐emerged BF.7, BQ.1, XBB. As several T‐cell‐reactive epitopes, which are highly conserved in sarbecoviruses, are displayed on the NP surface, it also provokes potent and cross‐reactive cellular immune responses in the respiratory tissue. Through intranasal delivery, it elicits robust mucosal immune responses and full protection without any adjuvants. Therefore, this intranasal mosaic NP vaccine can be further developed as a pan‐sarbecovirus vaccine to block the viral entrance from the upper respiratory tract. A mosaic receptor‐binding domain‐based nanoparticle vaccine is generated to elicit broad neutralizing against SARS‐CoV‐2 virus. The cross‐reactive cellular immune responses are further robustly induced by combinational conjugation of conserved T‐cell epitopes from sarbecoviruses. Through intranasal delivery without any adjuvants, our vaccine also elicits potent mucosal immune responses to combat the virus infection. Because of the rapid mutation and high airborne transmission of SARS-CoV-2, a universal vaccine preventing the infection in the upper respiratory tract is particularly urgent. Here, a mosaic receptor-binding domain (RBD) nanoparticle (NP) vaccine is developed, which induces more RBD-targeted type IV neutralizing antibodies (NAbs) and exhibits broad cross-protective activity against multiple SARS-CoV-2 sublineages including the newly-emerged BF.7, BQ.1, XBB. As several T-cell-reactive epitopes, which are highly conserved in sarbecoviruses, are displayed on the NP surface, it also provokes potent and cross-reactive cellular immune responses in the respiratory tissue. Through intranasal delivery, it elicits robust mucosal immune responses and full protection without any adjuvants. Therefore, this intranasal mosaic NP vaccine can be further developed as a pan-sarbecovirus vaccine to block the viral entrance from the upper respiratory tract. |
| Author | Lin, Yingtong Li, Rong Zhang, Hui Deng, Jieyi Wu, Shijian Feng, Jinzhu Liu, Bingfeng Zhang, Yiwen Zhang, Xu Zhang, Yongli Zhou, Mo Xi, Zhihui Liu, Jie Lin, Keming Liang, Chaofeng Chen, Ran Pu, Zeyu He, Xin Liu, Yingying Zhang, Xiantao |
| AuthorAffiliation | 1 Institute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 China 2 Guangzhou National Laboratory Bio‐Island Guangzhou 510320 China |
| AuthorAffiliation_xml | – name: 2 Guangzhou National Laboratory Bio‐Island Guangzhou 510320 China – name: 1 Institute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 China |
| Author_xml | – sequence: 1 givenname: Xiantao surname: Zhang fullname: Zhang, Xiantao organization: Institute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 China – sequence: 2 givenname: Shijian surname: Wu fullname: Wu, Shijian organization: Institute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 China – sequence: 3 givenname: Jie surname: Liu fullname: Liu, Jie organization: Institute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 China – sequence: 4 givenname: Ran surname: Chen fullname: Chen, Ran organization: Institute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 China – sequence: 5 givenname: Yongli surname: Zhang fullname: Zhang, Yongli organization: Institute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 China – sequence: 6 givenname: Yingtong surname: Lin fullname: Lin, Yingtong organization: Institute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 China – sequence: 7 givenname: Zhihui surname: Xi fullname: Xi, Zhihui organization: Institute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 China – sequence: 8 givenname: Jieyi surname: Deng fullname: Deng, Jieyi organization: Institute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 China – sequence: 9 givenname: Zeyu surname: Pu fullname: Pu, Zeyu organization: Institute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 China – sequence: 10 givenname: Chaofeng surname: Liang fullname: Liang, Chaofeng organization: Institute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 China – sequence: 11 givenname: Jinzhu surname: Feng fullname: Feng, Jinzhu organization: Institute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 China – sequence: 12 givenname: Rong surname: Li fullname: Li, Rong organization: Institute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 China – sequence: 13 givenname: Keming surname: Lin fullname: Lin, Keming organization: Institute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 China – sequence: 14 givenname: Mo surname: Zhou fullname: Zhou, Mo organization: Institute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 China – sequence: 15 givenname: Yingying surname: Liu fullname: Liu, Yingying organization: Institute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 China – sequence: 16 givenname: Xu surname: Zhang fullname: Zhang, Xu organization: Institute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 China – sequence: 17 givenname: Bingfeng surname: Liu fullname: Liu, Bingfeng organization: Institute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 China – sequence: 18 givenname: Yiwen surname: Zhang fullname: Zhang, Yiwen organization: Institute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 China – sequence: 19 givenname: Xin orcidid: 0000-0002-2131-2092 surname: He fullname: He, Xin organization: Institute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 China – sequence: 20 givenname: Hui orcidid: 0000-0003-3620-610X surname: Zhang fullname: Zhang, Hui organization: Institute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 China, Guangzhou National Laboratory Bio‐Island Guangzhou 510320 China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37526323$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1ks1u1DAQxyNUREvplSOyxIXLLv6Oc0KrVYGVWqi60KvlOE7qVWJv42RRbzwCL8DL8STMstuqrcTFY3l-85_xzLzMDkIMLsteEzwlGNP3ptqkKcWUYYIZf5YdUVKoCVOcHzy4H2YnKa0wxkSwnBP1IjtkuaCSUXaU_Z6h85iMt-iLCXFt-sHb1qErY60PDp223vohoYs4uDCg89EC3KJF143gvXRpHUNy6IcfrtHSN8HX3hoA531M6c_PXxc9BNrBx4BmYDZ-uEWmMT6krVg7-DUkW84ul8DO4xWcFC3HsoXcpnHpVfa8Nm1yJ3t7nH3_ePpt_nly9vXTYj47m1iuxDBR8H2qVEEKxiQmObSjrDjhrqqJEJiBWwpHCadUYlMYKaTIrQI3x5Qay46zxU63imal173vTH-ro_H630PsG73vjBaGSlI5W9Wu4KXgBZXKOSIFKTkvSAVaH3Za67HsXGWhb71pH4k-9gR_rZu40QQLiiXDoPBur9DHm9GlQXc-Wde2Jrg4Jk1hqFIRwgigb5-gqzj2AXoFlFSC5iKnQL15WNJ9LXdrAADfAXY7t97VGqZutmODCn0Lpentwuntwun7hYOw6ZOwO-X_BPwFvufaaQ |
| CitedBy_id | crossref_primary_10_1038_s41392_024_02043_4 crossref_primary_10_1002_ange_202412294 crossref_primary_10_1021_acsnano_4c12212 crossref_primary_10_1080_21645515_2023_2300157 crossref_primary_10_3390_vaccines12080890 crossref_primary_10_3390_vaccines12010037 crossref_primary_10_1002_mco2_70056 crossref_primary_10_2147_IJN_S468695 crossref_primary_10_3390_v16050803 crossref_primary_10_1371_journal_pone_0302243 crossref_primary_10_3390_v17010129 crossref_primary_10_1016_j_medidd_2024_100198 crossref_primary_10_1038_s41467_024_45495_6 crossref_primary_10_1186_s12967_024_05159_x crossref_primary_10_1002_anie_202412294 |
| Cites_doi | 10.1038/s41586-022-04441-6 10.1056/NEJMc2119236 10.1126/sciimmunol.add4853 10.1126/science.abi4506 10.1038/s41467-022-31721-6 10.1038/s41392-021-00848-1 10.1016/S0140-6736(20)30251-8 10.1016/j.cell.2022.11.030 10.1038/s41467-022-30222-w 10.1038/s41586-022-04479-6 10.1126/science.abf6840 10.1016/j.celrep.2021.110256 10.1038/d41573-022-00074-6 10.1126/science.abq0839 10.1021/acsnano.0c08379 10.1126/science.abo2523 10.1016/j.cell.2021.06.029 10.1056/NEJMoa2116597 10.1038/s41586-022-04865-0 10.1016/j.immuni.2020.11.015 10.1016/j.cell.2021.01.035 10.1038/s41586-020-2012-7 10.1002/advs.202105378 10.1038/s41392-021-00852-5 10.1038/s41598-020-74949-2 10.1038/s41586-021-03841-4 10.1038/s41423-021-00736-2 10.1016/j.it.2022.01.009 10.1038/s41565-020-0648-y 10.1038/s41586-021-03365-x 10.1038/s41467-019-12080-1 10.1056/NEJMoa2118946 10.1038/s41586-021-03594-0 10.1038/d41586-023-00220-z |
| ContentType | Journal Article |
| Copyright | 2023 The Authors. Advanced Science published by Wiley-VCH GmbH. 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2023 The Authors. Advanced Science published by Wiley‐VCH GmbH |
| Copyright_xml | – notice: 2023 The Authors. Advanced Science published by Wiley-VCH GmbH. – notice: 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2023 The Authors. Advanced Science published by Wiley‐VCH GmbH |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7XB 88I 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO GNUQQ GUQSH HCIFZ M2O M2P MBDVC PHGZM PHGZT PIMPY PKEHL PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
| DOI | 10.1002/advs.202301034 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) ProQuest Central (purchase pre-March 2016) Science Database (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Coronavirus Research Database ProQuest Central ProQuest Central Student ProQuest Research Library SciTech Premium Collection Research Library Science Database Research Library (Corporate) Proquest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Research Library Prep ProQuest Science Journals (Alumni Edition) ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Basic ProQuest Central Essentials ProQuest Science Journals ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Central China ProQuest Central ProQuest One Academic UKI Edition ProQuest Central Korea ProQuest Research Library ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Publicly Available Content Database CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) |
| EISSN | 2198-3844 |
| EndPage | n/a |
| ExternalDocumentID | oai_doaj_org_article_5a261decdfe94b549268ee1651b4491d PMC10520630 37526323 10_1002_advs_202301034 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Emergency Key Program of Guangzhou National Laboratory grantid: EKPG21-24 – fundername: Natural Science Foundation of China grantid: 92169201 – fundername: Special Research and Development Program of Guangzhou grantid: 202008070010 – fundername: Exchange Program of NSFC grantid: 82150710553 – fundername: National Key Research and Development Program of China grantid: 2022YFC0870700 – fundername: ; grantid: 92169201 – fundername: ; grantid: 2022YFC0870700 – fundername: Emergency Key Program of Guangzhou National Laboratory grantid: EKPG21‐24 |
| GroupedDBID | 0R~ 1OC 24P 53G 5VS 88I 8G5 AAFWJ AAHHS AAYXX AAZKR ABDBF ABUWG ACCFJ ACCMX ACGFS ACUHS ACXQS ADBBV ADKYN ADMLS ADZMN ADZOD AEEZP AEQDE AFBPY AFKRA AFPKN AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN AOIJS AVUZU AZQEC BCNDV BENPR BPHCQ BRXPI CCPQU CITATION DWQXO EBS EJD GNUQQ GODZA GROUPED_DOAJ GUQSH HCIFZ HYE IAO IGS ITC KQ8 M2O M2P O9- OK1 PHGZM PHGZT PIMPY PQQKQ PROAC ROL RPM AAMMB AEFGJ AGXDD AIDQK AIDYY CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK COVID MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO WIN 5PM |
| ID | FETCH-LOGICAL-c485t-8103288919336017010bd414edf1550310365e2142260a9a65657c8edf4022ac3 |
| IEDL.DBID | DOA |
| ISSN | 2198-3844 |
| IngestDate | Wed Aug 27 01:08:03 EDT 2025 Thu Aug 21 18:36:40 EDT 2025 Fri Sep 05 07:58:52 EDT 2025 Fri Jul 25 03:11:32 EDT 2025 Mon Jul 21 05:56:35 EDT 2025 Thu Apr 24 23:03:22 EDT 2025 Tue Jul 01 03:59:56 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 27 |
| Keywords | mucosal immune responses SARS-CoV-2 mosaic nanoparticle vaccine broad neutralizing antibody universal vaccines |
| Language | English |
| License | 2023 The Authors. Advanced Science published by Wiley-VCH GmbH. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c485t-8103288919336017010bd414edf1550310365e2142260a9a65657c8edf4022ac3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-3620-610X 0000-0002-2131-2092 |
| OpenAccessLink | https://doaj.org/article/5a261decdfe94b549268ee1651b4491d |
| PMID | 37526323 |
| PQID | 2868527572 |
| PQPubID | 4365299 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_5a261decdfe94b549268ee1651b4491d pubmedcentral_primary_oai_pubmedcentral_nih_gov_10520630 proquest_miscellaneous_2844681131 proquest_journals_2868527572 pubmed_primary_37526323 crossref_citationtrail_10_1002_advs_202301034 crossref_primary_10_1002_advs_202301034 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-09-00 |
| PublicationDateYYYYMMDD | 2023-09-01 |
| PublicationDate_xml | – month: 09 year: 2023 text: 2023-09-00 |
| PublicationDecade | 2020 |
| PublicationPlace | Germany |
| PublicationPlace_xml | – name: Germany – name: Weinheim – name: Hoboken |
| PublicationTitle | Advanced science |
| PublicationTitleAlternate | Adv Sci (Weinh) |
| PublicationYear | 2023 |
| Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc Wiley |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc – name: Wiley |
| References | e_1_2_9_10_2 e_1_2_9_11_1 e_1_2_9_10_1 e_1_2_9_13_1 e_1_2_9_10_3 e_1_2_9_11_2 e_1_2_9_12_1 e_1_2_9_15_1 e_1_2_9_14_1 e_1_2_9_17_1 e_1_2_9_15_2 e_1_2_9_16_1 e_1_2_9_19_1 e_1_2_9_18_1 e_1_2_9_20_1 e_1_2_9_4_5 e_1_2_9_7_2 e_1_2_9_8_1 e_1_2_9_4_4 e_1_2_9_7_1 e_1_2_9_4_3 e_1_2_9_6_1 e_1_2_9_4_2 e_1_2_9_5_1 e_1_2_9_4_1 e_1_2_9_2_2 e_1_2_9_3_1 e_1_2_9_2_1 e_1_2_9_1_1 e_1_2_9_9_3 e_1_2_9_8_3 e_1_2_9_9_2 e_1_2_9_8_2 e_1_2_9_9_1 |
| References_xml | – ident: e_1_2_9_4_1 doi: 10.1038/s41586-022-04441-6 – ident: e_1_2_9_4_3 doi: 10.1056/NEJMc2119236 – ident: e_1_2_9_7_1 doi: 10.1126/sciimmunol.add4853 – ident: e_1_2_9_8_3 doi: 10.1126/science.abi4506 – ident: e_1_2_9_9_2 doi: 10.1038/s41467-022-31721-6 – ident: e_1_2_9_20_1 doi: 10.1038/s41392-021-00848-1 – ident: e_1_2_9_2_2 doi: 10.1016/S0140-6736(20)30251-8 – ident: e_1_2_9_6_1 doi: 10.1016/j.cell.2022.11.030 – ident: e_1_2_9_8_2 doi: 10.1038/s41467-022-30222-w – ident: e_1_2_9_4_2 doi: 10.1038/s41586-022-04479-6 – ident: e_1_2_9_8_1 doi: 10.1126/science.abf6840 – ident: e_1_2_9_10_3 doi: 10.1016/j.celrep.2021.110256 – ident: e_1_2_9_3_1 doi: 10.1038/d41573-022-00074-6 – ident: e_1_2_9_12_1 doi: 10.1126/science.abq0839 – ident: e_1_2_9_11_2 doi: 10.1021/acsnano.0c08379 – ident: e_1_2_9_7_2 doi: 10.1126/science.abo2523 – ident: e_1_2_9_9_3 doi: 10.1016/j.cell.2021.06.029 – ident: e_1_2_9_17_1 doi: 10.1056/NEJMoa2116597 – ident: e_1_2_9_4_4 doi: 10.1038/s41586-022-04865-0 – ident: e_1_2_9_10_1 doi: 10.1016/j.immuni.2020.11.015 – ident: e_1_2_9_15_2 doi: 10.1016/j.cell.2021.01.035 – ident: e_1_2_9_1_1 doi: 10.1038/s41586-020-2012-7 – ident: e_1_2_9_10_2 doi: 10.1002/advs.202105378 – ident: e_1_2_9_4_5 doi: 10.1038/s41392-021-00852-5 – ident: e_1_2_9_15_1 doi: 10.1038/s41598-020-74949-2 – ident: e_1_2_9_9_1 doi: 10.1038/s41586-021-03841-4 – ident: e_1_2_9_19_1 doi: 10.1038/s41423-021-00736-2 – ident: e_1_2_9_2_1 doi: 10.1016/j.it.2022.01.009 – ident: e_1_2_9_14_1 doi: 10.1038/s41565-020-0648-y – ident: e_1_2_9_16_1 doi: 10.1038/s41586-021-03365-x – ident: e_1_2_9_13_1 doi: 10.1038/s41467-019-12080-1 – ident: e_1_2_9_18_1 doi: 10.1056/NEJMoa2118946 – ident: e_1_2_9_11_1 doi: 10.1038/s41586-021-03594-0 – ident: e_1_2_9_5_1 doi: 10.1038/d41586-023-00220-z |
| SSID | ssj0001537418 |
| Score | 2.3907847 |
| Snippet | Because of the rapid mutation and high airborne transmission of SARS‐CoV‐2, a universal vaccine preventing the infection in the upper respiratory tract is... Because of the rapid mutation and high airborne transmission of SARS-CoV-2, a universal vaccine preventing the infection in the upper respiratory tract is... Abstract Because of the rapid mutation and high airborne transmission of SARS‐CoV‐2, a universal vaccine preventing the infection in the upper respiratory... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e2301034 |
| SubjectTerms | Antibodies Antigens broad neutralizing antibody COVID-19 - prevention & control Disease transmission Humans Immunity, Mucosal Infections Ions mosaic nanoparticle vaccine mucosal immune responses Nanoparticles Pandemics Proteins SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 universal vaccines Vaccines Viruses |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagvXBBlGegICMhAYeoa8d2nBParrYqSFutdmnVW-TYzjZSlZQm5a_wd5lJvIFFwDV2Eifz8Lz8DSHvElYqaQsRZ57JWDAPIqW8A59HZ6J0tlQCDzgvztTpufhyKS9DwK0NZZVbndgratdYjJEfca205KlM-aebbzF2jcLsamihcZ_sgwrWwOf7x_Oz5epXlEUmCM-yRWuc8CPjviNKN1jebJKInd2oB-3_m6X5Z8HkbzvQySPyMJiOdDrQ-oDc8_VjchCEs6UfAoL0xyfkx5QumtZUloLyBK94uINeGItpdDq_rmzVtXTZgMHc0QUWrcODP-NREU9XQ9WspxiipetqU2M1ERCAzvAb4uWA7AD0pFM79J6gZmMqsDPpIpQn0vV0tY5nzUXM6RoDXbUHvdU-Jecn86-z0zh0YIit0LKLdQ-3pzOw8hKFSDtsUjjBhHclujbYo0xJz_vjuBOTGYVJVKthGNxSbmzyjOzVTe1fEJpyXyZpBv6J06LkzGhX-FRoq3RhlDcRibeUyG2AJ8cuGdf5AKzMc6RcPlIuIu_H-TcDMMc_Zx4jYcdZCKjdX2huN3mgQC4NuJLOW1f6TBQIW6e090xJVgiRMReRwy1b5EHK4RUjT0bk7TgM8olJF1P75g7ngMOtGUtYRJ4PXDSuJEklwuUnEdE7_LWz1N2RurrqMcAZ1i-pZPLy_-t6RR7gfxiK4g7JXnd751-DFdUVb4Ko_ATGzh32 priority: 102 providerName: ProQuest |
| Title | A Mosaic Nanoparticle Vaccine Elicits Potent Mucosal Immune Response with Significant Cross‐Protection Activity against Multiple SARS‐CoV‐2 Sublineages |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/37526323 https://www.proquest.com/docview/2868527572 https://www.proquest.com/docview/2844681131 https://pubmed.ncbi.nlm.nih.gov/PMC10520630 https://doaj.org/article/5a261decdfe94b549268ee1651b4491d |
| Volume | 10 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQuXBBlN9AqYyEBByixontOMd02aogUq02tOotcmynRKoSxG458wi8AC_HkzATZ6NdBOLCJZHiSWJ7ZuwZe_wNIS8T1khhah5mjomQMwcqJZ0Fn0dlvLGmkRwPOBdn8vScv78Ul1upvjAmzMMD-447EhpsfOuMbVzGa8QTk8o5JgWrOc-YxdE3yqItZ8qfD04QlmWD0hjFR9p-RXRusLhZlPCdWWgA6_-Thfl7oOTWzHNyj9wdTUaa-6ruk1uuu0_2R6Vc0dcjcvSbB-RHTot-pVtDYdAEb9i_QS-0we1zOr9uTbte0UUPhvKaFhisDh9-h0dEHF36aFlHcWmWlu1Vh1FE0PF0hm34-e37wmM6ACdpbnzWCaqvdAsWJi3GwERa5ssSaGf9BVxjWuIyV-dg1Fo9JOcn84-z03DMvxAarsQ6VAPYnsrAxksk4uywqLaccWcbdGwwQ5kULh4O40Y60xK3UI2CYnBKY22SR2Sv6zv3hNA0dk2SZuCdWMWbmGlla5dyZaSqtXQ6IOGGH5UZwckxR8Z15WGV4wr5V038C8irif6zh-X4K-UxsneiQjjt4QEIWTXyofqXkAXkYCMc1ajj8AsllYhTkcYBeTEVg3bilovuXH-DNOBuK8YSFpDHXpammiSpQLD8JCBqR8p2qrpb0rWfBgRwhtFLMome_o_GPSN3sLd84NwB2Vt_uXHPwdJa14fkdv62-FDC_Xh-tlgeDkr2C6ChLas |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELdG9wAviPGZMcBIIOAhWu04jvOAUFc6tWytqnab9pY5jtNFmpKxdiD-Ev4L_kbu8gVFwNte44vj5D5yZ9_9jpBXHkulb2Lhhpb5rmAWVEraBGIeFYo0MakUWOA8nsjhsfh06p9ukB9NLQymVTY2sTTUSWFwj3yXK6l8HvgB_3D52cWuUXi62rTQqMTiwH77CiHb8v3oI_D3Nef7g6P-0K27CrhGKH_lqhJCToXguXgS0WNYN04EEzZJ0V3HvlvSt7wsMe3qUEs8GDQKhiHU4tp4MO8tsimworVDNvcGk-ns166O7yEcTIMO2eW7OvmCqODg6cPEYu3vVzYJ-Jtn-2eC5m9_vP175G7tqtJeJVtbZMPm98lWbQyW9G2NWP3uAfneo-NiqTNDwVhDFF7dQU-0wWN7OrjITLZa0mkBDvqKjjFJHiYeYWmKpbMqS9dS3BKm82yRY_YSMJz28R3caYUkAfJDe6bqdUH1Qmfg19JxnQ5J573Z3O0XJy6nc9xYyy3YyeVDcnwjvHlEOnmR2yeEBtymXhBCPJQokXKmVRLbQCgjVayl1Q5xG05EpoZDx64cF1EF5Mwj5FzUcs4hb1r6ywoI5J-Ue8jYlgoBvMsLxdUiqjkQ-RpC18SaJLWhiBEmTyprmfRZLETIEofsNGIR1VYFHtHqgENetsNgD_CQR-e2uEYaCPAVYx5zyONKitqVeIGP8PyeQ9SafK0tdX0kz85LzHGG-VLS627_f10vyO3h0fgwOhxNDp6SO_hNqoS8HdJZXV3bZ-DBreLntdpQcnbTmvoTEKpWsw |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGJyFeEOOabYCRQMBD1NpxHOcBoa5rtTJaVS2b9hYcxymRpmSsHYhfwn_h13FOblAEvO01dh2n5-Jz7M_fIeS5x1Lpm1i4oWW-K5gFk5I2gZxHhSJNTCoFXnCeTOXRiXh35p9tkR_NXRiEVTY-sXTUSWFwj7zLlVQ-D_yAd9MaFjE7HL29-OxiBSk8aW3KaVQqcmy_fYX0bfVmfAiyfsH5aPhhcOTWFQZcI5S_dlVJJ6dCiGI8iUwyrBcnggmbpBi6Yw0u6VteXjft6VBLPCQ0Cpoh7eLaeDDuDbIdwKooOmT7YDidzX_t8PgeUsM0TJE93tXJF2QIh6gfBhYbK2FZMOBvUe6fYM3fVr_RHXK7Dltpv9KzHbJl87tkp3YMK_qqZq9-fY9879NJsdKZoeC4ISOvfkFPtcEjfDo8z0y2XtFZAcH6mk4QMA8Dj_GaiqXzCrFrKW4P00W2zBHJBMKnA_wGd1axSoAu0b6p6l5QvdQZxLh0UkMj6aI_X7iD4tTldIGbbLkFn7m6T06uRTYPSCcvcvuI0IDb1AtCyI0SJVLOtEpiGwhlpIq1tNohbiOJyNTU6Fih4zyqSJ15hJKLWsk55GXb_6IiBflnzwMUbNsLybzLB8XlMqolEPka0tjEmiS1oYiRMk8qa5n0WSxEyBKH7DdqEdUeBl7R2oNDnrXN4BvwwEfntrjCPpDsK8Y85pCHlRa1M_ECH6n6PYeoDf3amOpmS559KvnHGWKnpNfb_f-8npKbYKHR-_H0eI_cwr-kwubtk8768so-hmBuHT-prYaSj9dtqD8BA5Ja3w |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Mosaic+Nanoparticle+Vaccine+Elicits+Potent+Mucosal+Immune+Response+with+Significant+Cross%E2%80%90Protection+Activity+against+Multiple+SARS%E2%80%90CoV%E2%80%902+Sublineages&rft.jtitle=Advanced+science&rft.au=Xiantao+Zhang&rft.au=Shijian+Wu&rft.au=Jie+Liu&rft.au=Ran+Chen&rft.date=2023-09-01&rft.pub=Wiley&rft.eissn=2198-3844&rft.volume=10&rft.issue=27&rft.epage=n%2Fa&rft_id=info:doi/10.1002%2Fadvs.202301034&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_5a261decdfe94b549268ee1651b4491d |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2198-3844&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2198-3844&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2198-3844&client=summon |